9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

Estimated reading time: < 1 min

Condition: Non-small Cell Lung Cancer

Estimated Enrollment: 120

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Study Ia: Overall survival (OS),  Study Ib: Overall survival (OS),  Study II and III: Uptake of 68Ga-NOTA-AE105 in primary tumor lesion (dichotomized +/-), Study Ia: Progression free survival (PFS)

Interventions: 68Ga-NOTA-AE105 PET/CT,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), ,

Primary Completion Date: April 2023

Completion Date: October 2023

Last  Posted Date: November 21, 2016

Location: Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark

Website Link: https://ClinicalTrials.gov/show/NCT02755675

Was this article helpful?
Dislike 0